Ready to file: Alkermes planning to submit NDA for antipsychotic in third quarter
Alkermes plc said Tuesday that favorable phase III data on its long-acting injectable antipsychotic (LAI), aripiprazole lauroxil, will support its filing an FDA new drug application for the investigational schizophrenia treatment in the third quarter.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter